Payment overview · 2025
General Payments
$1,339.90
53 reported records · 15 companies
Healthcare provider profile · identity verified
Jacob Sauve, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MONTAGUE, MI · NPI 1902883770
Verified facts
What the public records show
CMS Open Payments records show Jacob Sauve, PAC received $1,339.90 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.88 | 20.4% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.73 | 15.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.50 | 12.4% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $130.26 | 9.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.71 | 7.7% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $90.27 | 6.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.03 | 5.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.05 | 4.6% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $45.54 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.63 | 3.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.14 | 3.0% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $39.57 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.50 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.78 | 1.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.31 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,339.90 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $239.22 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $204.73 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $204.73 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $126.87 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $115.77 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $115.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $102.71 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.13 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.03 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.03 | 4 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $56.95 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.95 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.16 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.55 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $45.54 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.28 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.14 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $39.57 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $39.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $39.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $39.57 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 70 |
| Lisinopril | Lisinopril | 291 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 290 | 41 |
| Omeprazole | Omeprazole | 223 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 53 |
| Eliquis | Apixaban | 178 | 31 |
| Glipizide Er | Glipizide | 167 | 36 |
| Morphine Sulfate Er | Morphine Sulfate | 164 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 41 |
| Metformin Hcl | Metformin Hcl | 141 | 35 |
| Tramadol Hcl | Tramadol Hcl | 141 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 38 |
| Jardiance | Empagliflozin | 131 | 25 |
| Gabapentin | Gabapentin | 129 | 25 |
| Prednisone | Prednisone | 128 | 52 |
| Lorazepam | Lorazepam | 124 | 22 |
| Trazodone Hcl | Trazodone Hcl | 122 | 21 |
| Furosemide | Furosemide | 117 | 40 |
| Metformin Hcl Er | Metformin Hcl | 107 | 26 |
| Losartan Potassium | Losartan Potassium | 105 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 28 |
| Atenolol | Atenolol | 96 | 22 |
| Meloxicam | Meloxicam | 91 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 18 |
| Potassium Chloride | Potassium Chloride | 84 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 11 |
| Pregabalin | Pregabalin | 79 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 23 |
| Montelukast Sodium | Montelukast Sodium | 77 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 13 |
| Celecoxib | Celecoxib | 61 | 13 |
| Carvedilol | Carvedilol | 59 | 17 |
| Famotidine | Famotidine | 59 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 11 |
| Sertraline Hcl | Sertraline Hcl | 53 | 13 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Allopurinol | Allopurinol | 50 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Cephalexin | Cephalexin | 48 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 14 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 34 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 18 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Azithromycin | Azithromycin | 31 | 11 |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | 12 |
| Naproxen | Naproxen | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Dulera | Mometasone/Formoterol | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Azathioprine | Azathioprine | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,339.90 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, CAPLYTA, CHARTIS CATHETER, Cologuard Collection Kit, ELIQUIS, FARXIGA, Fluad, Flucelvax, JARDIANCE, Leqembi, NURTEC ODT, OTEZLA, Ozempic, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, REXULTI, Rybelsus, Saxenda, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, YUPELRI, ZAVZPRET, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error